CompletedNot applicableNCT00023530
Blood and Marrow Transplant Clinical Research Network
Studying Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- Principal Investigator
- Joseph AntinDana-Farber Cancer Institute
- Intervention
- fluconazole(drug)
- Eligibility
- 2 years · All sexes
- Timeline
- 2001 – 2006
Study locations (16)
- City of Hope National Medical Center, Duarte, California, United States
- University of California at San Diego, La Jolla, California, United States
- Stanford University, Palo Alto, California, United States
- University of Florida, Gainesville, Florida, United States
- Johns Hopkins University, Baltimore, Maryland, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- University of Michigan at Ann Arbor, Ann Arbor, Michigan, United States
- University of Minnesota Twin Cities, Minneapolis, Minnesota, United States
- Children's Mercy Hospital, Kansas City, Missouri, United States
- University of Nebraska Medical Center, Omaha, Nebraska, United States
- Sloan-Kettering Institute for Cancer Research, New York, New York, United States
- Duke University, Durham, North Carolina, United States
- Case Western Reserve University, Cleveland, Ohio, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- +1 more locations on ClinicalTrials.gov
Collaborators
Blood and Marrow Transplant Clinical Trials Network
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00023530 on ClinicalTrials.govOther trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06303193Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative NeoplasmsNational Cancer Institute (NCI)
- RECRUITINGNANCT07500753A Single-arm, Prospective Study of a Cladribine-Bridged LABU Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory MDS/AML in Elderly PatientsThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE3NCT07422480A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood TransfusionsTakeda
- RECRUITINGPHASE4NCT07486713Olutasidenib DDI Study in Patients With IDH1 Mutation Positive MalignanciesRigel Pharmaceuticals
- RECRUITINGPHASE1NCT07107126Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic SyndromesRemedy Plan, Inc.
- RECRUITINGPHASE1NCT07270978Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDSUniversity of Virginia
- RECRUITINGNANCT06781099Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or MyelofibrosisHospices Civils de Lyon
- RECRUITINGPHASE2NCT07228273Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid LeukemiaOHSU Knight Cancer Institute